Massari F.; Di Nunno V., Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8, «EUROPEAN UROLOGY», 2018, 74, pp. 12 - 13 [articolo]
Di Nunno V.; Santoni M.; Massari F., Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405–15, «EUROPEAN UROLOGY», 2018, 74, pp. 50 - 50 [articolo]
Massari F.; Di Nunno V.; Ardizzoni A., Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62–8, «EUROPEAN UROLOGY», 2018, 73, pp. 72 - 72 [articolo]
Di Nunno V.; Gatto L.; Santoni M.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Scarpelli M.; Montironi R.; Massari F., Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer, «FRONTIERS IN ONCOLOGY», 2018, 8, Article number: 397, pp. 1 - 9 [articolo]Open Access
Mosillo, Claudia; Ciccarese, Chiara; Bimbatti, Davide; Fantinel, Emanuela; Volta, Alberto Dalla; Bisogno, Iolanda; Zampiva, Ilaria; Santoni, Matteo; Massari, Francesco; Brunelli, Matteo; Montironi, Rodolfo; Tortora, Giampaolo; Iacovelli, Roberto, Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research, «CANCER TREATMENT REVIEWS», 2018, 67, pp. 29 - 33 [articolo]
Procopio G.; Prisciandaro M.; Iacovelli R.; Cortesi E.; Fornarini G.; Facchini G.; Carteni G.; Sabbatini R.; Del Bene G.; Galli L.; Caserta C.; Multari A.G.; Bregni M.; Massari F.; Buti S.; De Giorgi U.; Zustovich F.; Milella M.; Calabro F.; Mancini M.L.; Tortora G.; Vernieri C.; Santini D.; Soraru M.; Ricotta R.; Masini C.; Tucci M.; Fedeli S.L.; Ortega C.; Mecozzi A.; Ratta R.; Sternberg C.N.; Verzoni E., Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program, «CLINICAL GENITOURINARY CANCER», 2018, 16, pp. 945 - 951 [articolo]
Massari F, Di Nunno V, Gatto L, Santoni M, Schiavina R, Cosmai L, Brunocilla E, Ardizzoni A, Porta C, Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy., «TARGETED ONCOLOGY», 2018, 13, pp. 705 - 714 [articolo]
Massari, Francesco; Ciccarese, Chiara; Hes, Ondrej; Michal, Michal; Caliò, Anna; Fiorentino, Michelangelo; Giunchi, Francesca; D'Amuri, Alessandro; Sanguedolce, Francesca; Sabbatini, Roberto; Guida, Annalisa; Ardizzoni, Andrea; Porta, Camillo; Iacovelli, Roberto; Tortora, Giampaolo; Cima, Luca; Ortega, Cinzia; Lapini, Alberto; Martignoni, Guido; Brunelli, Matteo, The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome, «PATHOLOGY ONCOLOGY RESEARCH», 2018, 24, pp. 447 - 456 [articolo]
Massari, Francesco; Ciccarese, Chiara; Hes, Ondrej; Michal, Michal; Caliò, Anna; Fiorentino, Michelangelo; Giunchi, Francesca; D’Amuri, Alessandro; Sanguedolce, Francesca; Sabbatini, Roberto; Guida, Annalisa; Ardizzoni, Andrea; Porta, Camillo; Iacovelli, Roberto; Tortora, Giampaolo; Cima, Luca; Ortega, Cinzia; Lapini, Alberto; Martignoni, Guido; Brunelli, Matteo*, The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome, «PATHOLOGY ONCOLOGY RESEARCH», 2018, 24, pp. 447 - 456 [articolo]
Lopez-Beltran A.; Henriques V.; Cimadamore A.; Santoni M.; Cheng L.; Gevaert T.; Blanca A.; Massari F.; Scarpelli M.; Montironi R., The identification of immunological biomarkers in kidney cancers, «FRONTIERS IN ONCOLOGY», 2018, 8, Article number: 456, pp. 1 - 13 [articolo]Open Access
Iacovelli R.; Cossu Rocca M.; Galli L.; Sabbatini R.; De Giorgi U.; Santini D.; Facchini G.; Mosca A.; Atzori F.; Zucali P.; Fornarini G.; Massari F.; Buti S.; Ricotta R.; Masini C.; Toscani I.; Biasco E.; Guida A.; Lolli C.; De Lisi D.; Rossetti S.; Terrone C.; Scartozzi M.; Miggiano C.; Pastorino A.; Bersanelli M.; Carlo-Stella G.; Pinto C.; Nobili E.; Nole F.; Tortora G.; Porta C., The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma, «ANTI-CANCER DRUGS», 2018, 29, pp. 705 - 709 [articolo]
Santoni M.; Massari F.; Piva F.; Carrozza F.; Di Nunno V.; Cimadamore A.; Martignetti A.; Montironi R.; Battelli N., Tivozanib for the treatment of renal cell carcinoma, «EXPERT OPINION ON PHARMACOTHERAPY», 2018, 19, pp. 1021 - 1025 [articolo]
Cimadamore A.; Scarpelli M.; Piva F.; Massari F.; Gasparrini S.; Doria A.; Cheng L.; Lopez-Beltran A.; Montironi R., Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets, «FUTURE ONCOLOGY», 2017, 13, pp. 1105 - 1114 [articolo]
Ciccarese C.; Iacovelli R.; Brunelli M.; Massari F.; Bimbatti D.; Fantinel E.; De Marco V.; Porcaro A.B.; Martignoni G.; Artibani W.; Tortora G., Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies, «EUROPEAN JOURNAL OF CANCER», 2017, 83, pp. 237 - 246 [articolo]
Massari F.; Di Nunno V.; Ciccarese C.; Graham J.; Porta C.; Comito F.; Cubelli M.; Iacovelli R.; Heng D.Y.C., Adjuvant therapy in renal cell carcinoma, «CANCER TREATMENT REVIEWS», 2017, 60, pp. 152 - 157 [articolo]
